CJC-1295 w/ DAC
Stocked in 5mg, 10mg at MontanaPep in Great Falls, Montana. Sold for laboratory research use only.
| Size | Catalog no. | Price per vial |
|---|---|---|
| 5mg | CD5 | $45 |
| 10mg | CD10 | $85 |
Classification
Long-acting albumin-binding GHRH analogue; development halted in 2006
Structure and chemistry
DAC-modified CJC-1295 is a 30-residue peptide: the tetrasubstituted GHRH(1-29) backbone (D-Ala2, Gln8, Ala15, Leu27) plus a C-terminal lysine bearing a maleimidopropionyl Drug Affinity Complex linker. In vivo, this linker forms a covalent bond with circulating serum albumin, which is what extends the half-life from roughly 30 minutes to several days.
What the published research shows
The core published human evidence is the 2006 Phase 1 program by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism — two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults aged 21 to 61. A companion 2006 JCEM paper by Ionescu and Frohman examined whether GH pulsatility survives continuous GHRH-receptor stimulation. No Phase 2 or Phase 3 efficacy trial was ever completed; the Phase 2 program was halted.
Mechanism of action
A GHRH receptor agonist producing sustained rather than pulsatile receptor stimulation. Notably, published work found that endogenous GH secretion remained pulsatile during continuous CJC-1295 stimulation, with increased pulse amplitude and elevated trough levels driving the sustained IGF-1 rise.
Development history
Developed by ConjuChem Biotechnologies (Montreal, Canada) in the early 2000s using the company’s proprietary Drug Affinity Complex albumin-binding technology, and investigated for growth hormone deficiency and HIV-associated lipodystrophy.
Current regulatory status
Not approved by the FDA or any regulator. Development was halted in 2006 during a Phase 2 lipodystrophy trial following the death of a trial participant; investigators attributed the death to pre-existing coronary artery disease and judged it unrelated to the drug, but the program was never resumed. CJC-1295 was nominated to FDA’s bulk drug substances list for pharmacy compounding; the nomination was withdrawn.
Analytical testing
The DAC modification is part of molecular identity and adds roughly the mass of the linker. LC-MS or another suitable identity method is essential to confirm the DAC form specifically, since the no-DAC backbone is a different and much cheaper molecule.
Ordering from Great Falls
MontanaPep, also known as Montana Peptides, is an independently owned supplier based at 715 13th Ave S, Great Falls, Montana. Local pickup is available by arrangement, and we ship to research addresses across Montana including Billings, Missoula, Bozeman, Helena, Butte, Kalispell and Havre. Call (406) 799-0812 or email customerservice@montanapep.com.